Full Press Release Details
TherapeuticsMD, Inc. 8-K
Announces Second Quarter 2019 Financial Results
Net Revenue $3.1 Million for the Second Quarter of 2019-
Net Revenue for the Second Quarter of 2019 Above Guidance at $6.1 Million-
Raises Full-Year Net Revenue Guidance to Range of $29.45 Million to $34.20 Million-
Call Scheduled for 4:30 p.m. ET Today-
RATON, Fla. - August 6, 2019 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's
healthcare company, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.
are pleased to report a solid quarter that came in ahead of our expectations and believe the next few quarters will be transformative,"
said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. "As we move into the second half of the year, we plan
to conduct pre-launch activities for ANNOVERA and continue to expand market access for our menopause portfolio.
We expect IMVEXXY and BIJUVA to have extensive coverage for commercially insured lives by the end of the year.
We are pursuing preferred status for IMVEXXY on Medicare Part D plans and expect coverage decisions by the fourth quarter, which
is significant given the higher proportion of IMVEXXY Medicare Part D business."
Quarter and Recent Developments
of Second Quarter 2019 Financial Results
net revenues for the second quarter of 2019 increased 62%, to approximately $6.1 million, compared with net revenues of approximately
$3.8 million for the prior year's quarter. The increase was primarily due to sales of approximately $3.1 million of IMVEXXY
and $134,000 of BIJUVA in the second quarter of 2019, partially offset by a decrease in the company's prescription prenatal
vitamin business of approximately $940,000 from the comparable quarter in 2018.
revenues have been greatly affected by the company's co-pay assistance programs introduced to launch IMVEXXY and BIJUVA,
which allowed eligible enrolled patients to access the products at a reasonable cost of no more than $35 per prescription regardless
of insurance coverage. The company expects revenues related to IMVEXXY and BIJUVA will improve as commercial and Medicare Part
D payer coverage increases, and plans complete the process needed to adjudicate prescriptions at pharmacies.
and development (R&D) expenses for the second quarter of 2019 decreased to approximately $5.0 million, compared with approximately
$6.8 million for the prior year's quarter. R&D costs decreased primarily as a result of transferring certain costs and
activities from R&D expenses to support commercial and launch efforts after the FDA approval of IMVEXXY and BIJUVA. R&D
expenses include costs related to manufacturing validation as well as pre-clinical work to support the company's R&D
general and administrative (SG&A) expenses increased for the second quarter of 2019 to approximately $41.4 million, compared
with approximately $29.5 million for the prior year's quarter. The increase in second quarter 2019 SG&A expenses was
primarily a result of increased expenses associated with sales and marketing efforts and personnel costs to support the launch
and commercialization of IMVEXXY and BIJUVA, including costs related to sales force expansion, outsourced sales personnel and
their related expenses, physician education and product samples, and other expenses related to product commercialization. The
company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA, prepares for the launch
of ANNOVERA, and continues to support its growing business and commercialization of its products.
the second quarter of 2019, the company took a one-time charge for extinguishment of debt of approximately $10.1 million in connection
with the refinancing of its term loan. As a result of the foregoing, net loss increased to approximately $55.2 million, or $0.23
per basic and diluted share, for the second quarter of 2019. Excluding the one-time charge for extinguishment of debt, the net
loss for the second quarter was approximately $45.2 million, or $0.19 per basic and diluted share, compared with approximately
$33.2 million, or $0.15 per basic and diluted share, for the second quarter of 2018.
of June 30, 2019, the company's cash on hand totaled approximately $182.8 million, compared with approximately $161.6 million
at December 31, 2018. Total outstanding debt, net of issuance costs, was approximately $194.1 million as of June 30, 2019.
following table outlines TherapeuticsMD's revised 2019 financial guidance (in millions).
| 3Q 2019 | 4Q 2019 | FY 2019 | ||||
| Original | Revised | Original | Revised | Original | Revised | |
| FDA-Approved Products | $4.50-$6.50 | Unchanged | $11.00-$13.00 | Unchanged | $20.00-$24.5 | $20.75-$24.75 |
| Prescription Prenatal Vitamins | $1.75-$2.25 | $2.25-$2.50 | $1.50-$2.00 | $1.75-$2.25 | $7.15-$8.65 | $8.70-$9.45 |
| Total Net Revenues | $6.25-$8.75 | $6.75-$9.00 | $12.50-$15.00 | $12.75-$15.25 | $27.10-$33.10 | $29.45-$34.20 |
Call and Webcast Details
will host a conference call and audio webcast today at 4:30 p.m. ET to discuss these financial results and provide a
| Date: | Tuesday, August 6, 2019 | |
| Time: | 4:30 p.m. ET | |
| Telephone Access (US): | 866-665-9531 | |
| Telephone Access (International): | 724-987-6977 | |
| Access Code for All Callers: | 1392883 |
live webcast and audio archive for the event may be accessed on the home page or from the "Investors & Media"
section of the TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation
to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will
be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for
replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international
404-537-3406 and Conference ID: 1392883.
see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:
About TherapeuticsMD,
Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for
women. Our products are designed to address the unique changes and challenges women experience
through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management.
The company is committed to advancing the health of women and championing awareness of their
and on Facebook: TherapeuticsMD.
press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may
include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and strategies as well as
statements, other than historical facts, that address activities, events or developments that the company intends, expects,
projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology
such as "believes," "hopes," "may," "anticipates," "should,"
"intends," "plans," "will," "expects," "estimates,"
"projects," "positioned," "strategy" and similar expressions and are based on assumptions
and assessments made in light of management's experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release
are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important
factors that could cause actual results, developments and business decisions to differ materially from
forward-looking statements are described in the sections titled "Risk Factors" in the company's filings
with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q, as well as reports on Form 8-K, and include the following: the company's ability to maintain or increase
sales of its products; the company's ability to develop and commercialize IMVEXXY ,
ANNOVERA , BIJUVA and its hormone therapy drug candidates and obtain additional financing
necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan
facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of
the company's current or future approved products or preclude the approval of the company's future drug
candidates; the length, cost and uncertain results of future clinical trials; the company's reliance on third parties
to conduct its manufacturing, research and development and clinical trials; the ability of the company's licensees to
commercialize and distribute the company's products; the availability of reimbursement from
government authorities and health insurance companies for the company's products; the impact of product liability
lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the
company's common stock and the concentration of power in its stock ownership. PDF copies of the company's
historical press releases and financial tables can be viewed and downloaded at its
President, Investor Relations
INC. AND SUBSIDIARIES
| June 30, 2019 | December 31, 2018 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 182,846,301 | $ | 161,613,077 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively | 18,383,012 | 11,063,821 | ||||||
| Inventory | 7,494,440 | 3,267,670 | ||||||
| Other current assets | 7,739,048 | 10,834,693 | ||||||
| Total current assets | 216,462,801 | 186,779,261 | ||||||
| Fixed assets, net | 1,432,137 | 472,683 | ||||||
| Other Assets: | ||||||||
| License rights | 20,000,000 | 20,000,000 | ||||||
| Intangible assets, net | 4,688,114 | 4,092,679 | ||||||
| Other assets | 3,635,227 | 324,855 | ||||||
| Security deposit | 334,866 | 314,446 | ||||||
| Total other assets | 28,658,207 | 24,731,980 | ||||||
| Total assets | $ | 246,553,145 | $ | 211,983,924 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 19,499,238 | $ | 22,743,841 | ||||
| Other current liabilities | 22,376,617 | 18,334,948 | ||||||
| Total current liabilities | 41,875,855 | 41,078,789 | ||||||
| Long-Term Liabilities: | ||||||||
| Long-term debt | 194,095,220 | 73,381,014 | ||||||
| Operating lease liability | 2,488,101 | - | ||||||
| Total liabilities | 238,459,176 | 114,459,803 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' Equity: | ||||||||
| Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||
| Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively | 241,222 | 240,463 | ||||||
| Additional paid-in capital | 621,871,919 | 616,559,938 | ||||||
| Accumulated deficit | (614,019,172 | ) | (519,276,280 | ) | ||||
| Total stockholders' equity | 8,093,969 | 97,524,121 | ||||||
| Total liabilities and stockholders' equity | $ | 246,553,145 | $ | 211,983,924 |
INC. AND SUBSIDIARIES
STATEMENTS OF OPERATIONS
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| Revenues, net | $ | 6,078,865 | $ | 3,763,010 | $ | 10,025,516 | $ | 7,536,402 | ||||||||
| Cost of goods sold | 1,248,860 | 454,161 | 2,011,687 | 1,087,784 | ||||||||||||
| Gross profit | 4,830,005 | 3,308,849 | 8,013,829 | 6,448,618 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales, general, and administrative | 41,387,451 | 29,466,770 | 76,251,533 | 50,224,007 | ||||||||||||
| Research and development | 4,964,368 | 6,798,380 | 11,282,250 | 13,837,677 | ||||||||||||
| Depreciation and amortization | 115,059 | 65,603 | 221,997 | 125,224 | ||||||||||||
| Total operating expenses | 46,466,878 | 36,330,753 | 87,755,780 | 64,186,908 | ||||||||||||
| Operating loss | (41,636,873 | ) | (33,021,904 | ) | (79,741,951 | ) | (57,738,290 | ) | ||||||||
| Other (expense) income | ||||||||||||||||
| Loss on extinguishment of debt | (10,057,632 | ) | - | (10,057,632 | ) | - | ||||||||||
| Miscellaneous income | 486,597 | 334,238 | 1,175,318 | 648,795 | ||||||||||||
| Interest expense | (4,028,609 | ) | (531,382 | ) | (6,118,627 | ) | (531,382 | ) | ||||||||
| Total other (expense) income | (13,599,644 | ) | (197,144 | ) | (15,000,941 | ) | 117,413 | |||||||||
| Loss before income taxes | (55,236,517 | ) | (33,219,048 | ) | (94,742,892 | ) | (57,620,877 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (55,236,517 | ) | $ | (33,219,048 | ) | $ | (94,742,892 | ) | $ | (57,620,877 | ) | ||||
| Loss per share, basic and diluted: | ||||||||||||||||
| Net loss per share, basic and diluted | $ | (0.23 | ) | $ | (0.15 | ) | $ | (0.39 | ) | $ | (0.27 | ) | ||||
| Weighted average number of common shares outstanding, basic and diluted | 241,221,840 | 216,640,186 | 241,114,532 | 216,583,067 |
INC. AND SUBSIDIARIES
STATEMENTS OF CASH FLOWS
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2019 | 2018 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | (94,742,892 | ) | $ | (57,620,877 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation of fixed assets | 133,049 | 79,201 | ||||||
| Amortization of intangible assets | 88,948 | 46,023 | ||||||
| Write off of patent and trademark cost | 78,864 | - | ||||||
| Non-cash operating lease expense | 443,734 | - | ||||||
| Provision for doubtful accounts | 167,500 | 38,024 | ||||||
| Loss on extinguishment of debt | 10,057,632 | - | ||||||
| Share-based compensation | 5,224,212 | 4,128,440 | ||||||
| Amortization of deferred financing fees | 316,880 | 30,155 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (7,486,691 | ) | (1,335,209 | ) | ||||
| Inventory | (4,226,770 | ) | (395,219 | ) | ||||
| Other current assets | 1,710,697 | 2,539,394 | ||||||
| Accounts payable | (3,244,603 | ) | 7,329,560 | |||||
| Accrued expenses and other liabilities | 2,801,717 | 561,615 | ||||||
| Net cash used in operating activities | (88,677,723 | ) | (44,598,893 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Patent costs | (763,247 | ) | (434,677 | ) | ||||
| Purchase of fixed assets | (1,092,504 | ) | (45,720 | ) | ||||
| Payment of security deposit | (20,420 | ) | (11,486 | ) | ||||
| Net cash used in investing activities | (1,876,171 | ) | (491,883 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds from exercise of options and warrants | 100,107 | 1,128,996 | ||||||
| Repayment of the Credit Agreement | (81,660,719 | ) | - | |||||
| Proceeds from the Financing Agreement | 200,000,000 | 75,000,000 | ||||||
| Payment of deferred financing fees | (6,652,270 | ) | (3,786,918 | ) | ||||
| Net cash provided by financing activities | 111,787,118 | 72,342,078 | ||||||
| Increase in cash | 21,233,224 | 27,251,302 | ||||||
| Cash, beginning of period | 161,613,077 | 127,135,628 | ||||||
| Cash, end of period | $ | 182,846,301 | $ | 154,386,930 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | $ | 6,989,570 | $ | - | ||||
| Cash paid for income taxes | $ | - | $ | - |